Pharmaceutical composition for controlled release of treprostinil
DE602019076941T2Active Publication Date: 2025-10-15PHARMOSA BIOPHARM INC
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- DE602019076941
- Authority / Receiving Office
- DE · DE
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2018-05-14
- Filing Date
- 2019-05-06
- Publication Date
- 2025-10-15
- Estimated Expiration
- 2039-05-06
AI Technical Summary
Technical Problem
Existing liposomal compositions for treprostinil suffer from burst release, leading to insoluble drug precipitates and side effects, and lack an extended release profile for sustained therapeutic efficacy.
Method used
A pharmaceutical composition with a specific treprostinil-to-phospholipid ratio of 0.035 or higher, utilizing a pH gradient between the internal and external medium, reduces burst release and extends treprostinil release from 2 to 72 hours, minimizing side effects in the upper respiratory tract.
Benefits of technology
The composition achieves controlled release of treprostinil, reducing side effects and extending therapeutic efficacy by minimizing burst release and maintaining effective drug levels for up to 72 hours, thereby reducing dosing frequency.
✦ Generated by Eureka AI based on patent content.
Need to check novelty before this filing date? Find Prior Art
No text content released.